» Articles » PMID: 1383404

Characterization of Two Antigenic Sites Recognized by Neutralizing Monoclonal Antibodies Directed Against the Fusion Glycoprotein of Human Respiratory Syncytial Virus

Overview
Journal J Gen Virol
Specialty Microbiology
Date 1992 Sep 1
PMID 1383404
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Two antigenic sites recognized by neutralizing monoclonal antibodies (MAbs) directed against the fusion (F) glycoprotein of human respiratory syncytial virus were mapped on the primary structure of the protein by (i) the identification of amino acid substitutions selected in antibody-escape mutants and (ii) the reactivity of synthetic peptides with MAbs. The first site contained several overlapping epitopes which were located within the trypsin-resistant amino-terminal third of the large F1 subunit. Only one of these epitopes was faithfully reproduced by a short synthetic peptide; the others might require specific local conformations to react with MAbs. The second antigenic site was located in a trypsin-sensitive domain of the F1 subunit towards the carboxy-terminal end of the cysteine-rich region. One of these epitopes was reproduced by synthetic peptides. In addition, mutagenized F protein with a substitution of serine for arginine at position 429 did not bind MAbs to the second site. These results are discussed in terms of F protein structure and the mechanisms of virus neutralization.

Citing Articles

A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus.

Lin M, Yin Y, Zhao X, Wang C, Zhu X, Zhan L Nat Commun. 2025; 16(1):1386.

PMID: 39910047 PMC: 11799228. DOI: 10.1038/s41467-025-56302-1.


KD-409, a Respiratory Syncytial Virus FG Chimeric Protein without the CX3C Chemokine Motif, Is an Efficient Respiratory Syncytial Virus Vaccine Preparation for Passive and Active Immunization in Mice.

Yamaue R, Torikai M, Terashima M, Mori H Vaccines (Basel). 2024; 12(7).

PMID: 39066391 PMC: 11281633. DOI: 10.3390/vaccines12070753.


Respiratory Syncytial Virus in Adult Patients at a Tertiary Care Hospital in Germany: Clinical Features and Molecular Epidemiology of the Fusion Protein in the Severe Respiratory Season of 2022/2023.

Honemann M, Maier M, Frille A, Thiem S, Bergs S, Williams T Viruses. 2024; 16(6).

PMID: 38932235 PMC: 11209376. DOI: 10.3390/v16060943.


Structural basis for respiratory syncytial virus and human metapneumovirus neutralization.

Miller R, Mousa J Curr Opin Virol. 2023; 61:101337.

PMID: 37544710 PMC: 10421620. DOI: 10.1016/j.coviro.2023.101337.


Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge.

Powell T, Jacobs A, Tang J, Cardenas E, Palath N, Daniels J Vaccines (Basel). 2022; 10(12).

PMID: 36560488 PMC: 9785538. DOI: 10.3390/vaccines10122078.